Pregnancy Risks With First Trimester GLP-1 Continuation - Takeaways - MDSpire

Pregnancy Risks With First Trimester GLP-1 Continuation

Claims-based target trial emulation found no clear association between continued GLP-1 receptor agonist use in early pregnancy and nonlive birth, fetal growth abnormalities, or major congenital malformations.

  • By

  • Andrea Surnit

  • June 17, 2026

  • 3 min

Share

  • 1

    Continuation of GLP-1 receptor agonists in the first trimester does not show a clear increase in nonlive birth or major congenital malformations.

  • 2

    The study analyzed 3,572 pregnancies, comparing outcomes between those who continued GLP-1 treatment and those who did not.

  • 3

    The adjusted risk ratio for nonlive birth was 1.09, indicating no significant difference in risk between treatment groups.

  • 4

    Elective termination rates were higher among patients who continued GLP-1 treatment, potentially due to various influencing factors.

  • 5

    The study's observational design has limitations, including potential residual confounding and imprecise estimates for some outcomes.

Original Source(s)

Pregnancy Risks With First Trimester GLP-1 Continuation

  • by Andrea Surnit

  • June 17, 2026

Related Content

Diabetes Risk Scores: Beyond Glucose

Multi-ancestry polygenic models identify high-risk patients traditional screening may miss.

Medical Oddities: Something Viral is Lurking in the Dust

Everyday things like yawns, tea, dust, and kimchi suddenly look medically important.

Women Overdue for Cancer Screenings

More than 80% of women who were partially up to date reported a wellness visit in the prior year, suggesting missed opportunities for screening engagement in primary care.